Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06918561 · ClinicalTrials.gov registry record · NA
Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds
A NA study of Open Wound, sponsored by NuScience Medical Biologics.
- Recruiting
- Registry status
- NA
- Development phase
- 132
- Enrollment target
- 3
- Study locations
NCT06918561: Recruiting NA study of Open Wound, sponsored by NuScience Medical Biologics.
NCT06918561 is a NA study of Open Wound that is actively recruiting participants, run by NuScience Medical Biologics. The registered enrollment target is 132 participants, above the 22-participant average among 3 other Open Wound trials with a reported enrollment target (500% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06918561, a NA study of Open Wound, is actively recruiting participants, sponsored by NuScience Medical Biologics.
- RECRUITING
- Registry status
- NA
- Development phase
- 132 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Primary Outcome
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure.
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER NeoThelium FT
Study Locations (3)
Louisiana
- MedCentris of Hammond - Hammond
- MedCentris of Slidell - Slidell
Mississippi
- MedCentris of D'iberville - D'Iberville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-10-01 |
| Phase | NA |
What NCT06918561 shows while recruiting
NCT06918561 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, above the 22-participant average among 3 other Open Wound trials with a reported enrollment target (500% higher).
The record links to 1 condition, with Open Wound appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT06918561 reports a single indexed study location in Louisiana, Mississippi.
Frequently Asked Questions
What is clinical trial NCT06918561 about?
NCT06918561 is a clinical study titled "Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds". This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
What is the current status of trial NCT06918561?
This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2025-10-16. Estimated completion is 2026-10-01.
What conditions does trial NCT06918561 study?
This clinical trial studies the following conditions: Open Wound.
What interventions are being tested in trial NCT06918561?
The interventions under investigation include: Standard of Care (OTHER), NeoThelium FT (OTHER).
Who is sponsoring clinical trial NCT06918561?
This trial is sponsored by NuScience Medical Biologics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06918561 being conducted?
This trial has 3 study locations across Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI